Business
GE HealthCare to Acquire Remaining 50% Stake in Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan, from Sumitomo Chemical
GE HealthCare to acquire 50% stake from Sumitomo Chemical to assume full ownership of NMP, subject to regulatory approvals As part of GE HealthCare, NMP,
About this update from Ge Healthcare Technologies Inc.
[{"type":"text","content":"\n\nGE HealthCare to acquire 50% stake from Sumitomo Chemical to assume full ownership of NMP, subject to regulatory approvals\n\n\n\nAs part of GE HealthCare, NMP, already a leading radiopharmaceutical company in Japan, will enhance patient access to next-generation radiopharmaceuticals that enable detection and diagnosis of disease\n\n\n\nAcquisition positions NMP to become partner of choice for global innovators looking to bring novel radiopharmaceuticals to Japan and other Asian markets\n\n\n\nTransaction bolsters GE HealthCare’s Pharmaceutical Diagnostics segment and demonstrates its commitment to shaping the future of Molecular Imaging\n\n\n\n CHALFONT ST GILES, England--(BUSINESS WIRE)--\nGE HealthCare (Nasdaq: GEHC) has agreed to acquire full ownership of Nihon Medi-Physics Co., Ltd (NMP), by purchasing from Sumitomo Chemical (TYO: 4005) the 50% stake it does not already own. As part of GE HealthCare, NMP can build on its expertise developing and manufacturing proprietary and in-licensed radiopharmaceuticals used in single photon emission computed tomography (SPECT) and positron emission tomography (PET) molecular imaging procedures to detect and diagnose disease. Sumitomo and GE HealthCare expect the agreement to close in early 2025, subject to regulatory approvals.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241201060498/en/Nihon Medi-Physics headquarters and woman looking at molecular imaging images (Photo: Business Wire)\nNMP’s product portfolio includes GE HealthCare radiopharmaceuticals used to enable clinical images across neurology, cardiology and oncology procedures, such as its amyloid visualization radiotracer, VIZAMYL® Injection (Flutemetamol (18F) Injection), used in the Alzheimer’s pathway; DaTSCAN® Injection (Ioflupane (¹²³I) injection) used to evaluate patients with suspected Parkinson’s Disease or Dementia with Lewy Bodies; and MYOVIEW® (Technetium (99mTc) Tetrofosmin), used in SPECT myocardial perfusion imaging for the evaluation of known or suspected coronary artery disease. NMP, headquartered in Tokyo, was formed in 1973 and generated revenues of 28.2B JPY (~$183M) in 2023. In addition to 13 manufacturing facilities, NMP also focuses on research and development, including nonclinical and clinical development of radiotracers and theran...